AstraZeneca (AZN) News Today £104.36 -60.00 (-0.57%) As of 12:42 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityBuy This Stock AZN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period AstraZeneca’s anselamimab treatment fails to meet main trial goal; shares slipJuly 16 at 6:18 AM | uk.investing.comAstraZeneca’s rare disease drug falls short in late-stage trialJuly 16 at 6:18 AM | msn.comAstraZeneca drug lowers high blood pressure in late-stage study; shares riseJuly 15 at 10:18 AM | msn.comAstraZeneca PLC (AZN) Secures EU Approval for ImfinziJuly 15 at 10:18 AM | msn.comAstraZeneca Meets All Key Goals in Phase III Hypertension StudyJuly 15 at 10:18 AM | msn.comAstraZeneca (LSE:AZN) Unveils Promising Phase III Results For Baxdrostat In Hypertension TrialJuly 14 at 3:15 PM | finance.yahoo.comAstraZeneca slips Friday, underperforms marketJuly 11, 2025 | marketwatch.comAstraZeneca (AZN) Receives a Buy from Berenberg BankJuly 10, 2025 | theglobeandmail.comAstraZeneca (AZN) Receives a Hold from Deutsche BankJuly 10, 2025 | theglobeandmail.comAstraZeneca climbs Tuesday, outperforms marketJuly 8, 2025 | marketwatch.comTop Analyst Reports for T-Mobile, AstraZeneca & ComcastJuly 8, 2025 | msn.comAstraZeneca's (AZN) Hold Rating Reaffirmed at Deutsche Bank AktiengesellschaftJuly 8, 2025 | marketbeat.comAstraZeneca: Just What The Doctor OrderedJuly 8, 2025 | seekingalpha.comAstraZeneca (LSE:AZN) Wins EU Approval For Imfinzi In Muscle-Invasive Bladder CancerJuly 7, 2025 | finance.yahoo.comSummit Therapeutics Stock Soars on Report of $15B AstraZeneca Partnership TalksJuly 3, 2025 | msn.comAstraZeneca In Talks To License Summit Therapeutics’ Experimental Lung Cancer Drug: ReportJuly 3, 2025 | msn.comAstraZeneca considers moving listing to US, the Times reportsJuly 2, 2025 | msn.comWill AstraZeneca be the next FTSE 100 stock to move to the US?July 2, 2025 | msn.comAstraZeneca rallies Tuesday, outperforms marketJuly 1, 2025 | marketwatch.comAZN Stock Price Quote - MorningstarJuly 1, 2025 | morningstar.comMRakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025June 30, 2025 | uk.finance.yahoo.comEvotec (EVO) Joins NURTuRE-AKI Consortium to Advance Kidney Injury Drug DiscoveryJune 29, 2025 | msn.comAZN - AstraZeneca PLC ADR Price vs Fair Value - MorningstarJune 28, 2025 | morningstar.comMAstraZeneca (AZN) Scores FDA Approval for Datroway, First TROP2 ADC for Lung CancerJune 28, 2025 | msn.comAstraZeneca (LSE:AZN) Gains FDA Approval For Datroway In Treating Advanced Lung CancerJune 26, 2025 | uk.finance.yahoo.comAstraZeneca Presents Positive Phase I/II Data for Surovatamig in B-cell ALL at EHA 2025June 25, 2025 | msn.comAZN - AstraZeneca PLC ADR Key Metrics - MorningstarJune 24, 2025 | morningstar.comMAstraZeneca, GSK shares down after Trump threatens drug import tariffsJune 18, 2025 | investing.comAstraZeneca slips Tuesday, underperforms marketJune 17, 2025 | marketwatch.comAstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial CancerJune 15, 2025 | finance.yahoo.comAstraZeneca advances Thursday, outperforms marketJune 12, 2025 | marketwatch.comAt a bargain-basement valuation now, is AstraZeneca’s share price impossible for me to ignore?June 12, 2025 | uk.finance.yahoo.comAstraZeneca (LON:AZN) Share Price Passes Above Two Hundred Day Moving Average - Here's What HappenedJune 12, 2025 | marketbeat.comTracking George Soros's 13F Portfolio - Q1 2025 UpdateJune 12, 2025 | seekingalpha.comAmerican Century Focused International Growth Fund Q1 2025 CommentaryJune 11, 2025 | seekingalpha.comAstrazeneca (AZN) Outpaces Stock Market Gains: What You Should KnowJune 10, 2025 | msn.comAstraZeneca (LSE:AZN) Partners In Quantum Leap For Drug Development EfficiencyJune 10, 2025 | finance.yahoo.comIonQ, AstraZeneca, Nvidia and AWS show quantum-accelerated drug development workflowJune 9, 2025 | msn.comAstraZeneca: Fascinating Company With Lofty Ambitions - Just Not A Buy YetJune 7, 2025 | seekingalpha.comAstraZeneca wins EU backing for Imfinzi in bladder cancerMay 27, 2025 | msn.comAstraZeneca climbs Friday, outperforms marketMay 16, 2025 | marketwatch.comIs AstraZeneca (AZN) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom?May 13, 2025 | msn.comWhy did the AstraZeneca share price just fall, and what should we do?May 12, 2025 | msn.comAstraZeneca PLC (LON:AZN) Given Average Rating of "Moderate Buy" by BrokeragesMay 12, 2025 | marketbeat.comAstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment BrightensMay 9, 2025 | msn.comAstraZeneca advances Friday, outperforms marketMay 9, 2025 | marketwatch.comAstraZeneca slides Wednesday, underperforms marketMay 7, 2025 | marketwatch.comAstraZeneca Gets Approval For Oncology Drug To Treat Mantle Cell Lymphoma In EU: But Retail Sentiment DipsMay 6, 2025 | msn.comAstraZeneca (LSE:AZN) Announces Positive Results From Breztri Trials For Uncontrolled AsthmaMay 2, 2025 | finance.yahoo.comAstraZeneca’s Breztri Therapy Meets Primary Goals In Late-Stage Trials To Treat Asthma: Retail’s PositiveMay 2, 2025 | msn.com Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter. Email Address AZN Media Mentions By Week AZN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AZN News Sentiment▼0.200.97▲Average Medical News Sentiment AZN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AZN Articles This Week▼94▲AZN Articles Average Week Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GSK News Ithaca Energy News HUTCHMED News Indivior News Grainger News Origin Enterprises News Bloomsbury Publishing News Global Ports News India Capital Growth News Aura Energy News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:AZN) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s Little-Known Succession PlanYou could miss out on millions buying a house - even if prices rise Joel Litman is a millionaire member of ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AZN Stock Alerts